Matches in Wikidata for { <http://www.wikidata.org/entity/Q83385905> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q83385905 description "artículu científicu espublizáu n'abril de 2009" @default.
- Q83385905 description "im April 2009 veröffentlichter wissenschaftlicher Artikel" @default.
- Q83385905 description "scientific article published on 01 April 2009" @default.
- Q83385905 description "wetenschappelijk artikel" @default.
- Q83385905 description "наукова стаття, опублікована у квітні 2009" @default.
- Q83385905 name "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 name "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 type Item @default.
- Q83385905 label "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 label "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 prefLabel "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 prefLabel "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 P1433 Q83385905-178AE01F-85EC-4A73-8233-07830A294C14 @default.
- Q83385905 P1476 Q83385905-27996AC1-1E88-4264-BB8F-B4A4DC2FF651 @default.
- Q83385905 P2093 Q83385905-00F3DA31-82A3-4B9E-9E17-E6FD4B352853 @default.
- Q83385905 P2093 Q83385905-03E7768A-BC39-44ED-9A93-94E7A34DA053 @default.
- Q83385905 P2093 Q83385905-0E5AAF1A-3B55-418D-BF52-B7598C2EF0EE @default.
- Q83385905 P2093 Q83385905-23AE5F97-9A41-4DA0-ACC3-D35BDB5C710A @default.
- Q83385905 P2093 Q83385905-4EDC21B1-A5CB-44C5-8D39-692CF15C282A @default.
- Q83385905 P2093 Q83385905-50B4FB06-E151-4F8D-8D97-8BD71033313C @default.
- Q83385905 P2093 Q83385905-5A18D4BC-DD1D-41ED-997B-6C0A50F23968 @default.
- Q83385905 P2093 Q83385905-5FCF1602-38D8-4E41-9B62-5CA1C4B7C01F @default.
- Q83385905 P2093 Q83385905-606D8B46-3BF0-4FDA-91D1-1EC16F2888E3 @default.
- Q83385905 P2093 Q83385905-91AD3DB3-8397-4964-AAB5-D0C58486227C @default.
- Q83385905 P2093 Q83385905-D566A923-1A40-47EE-8B19-10AB8AAB3B05 @default.
- Q83385905 P2093 Q83385905-F7292DEA-01B5-40CD-89C1-97BEAD61E9E7 @default.
- Q83385905 P304 Q83385905-CC709558-AF08-4BD9-81B0-F9AE3E871760 @default.
- Q83385905 P31 Q83385905-26AF578C-A1EB-492F-8E20-B1C1F58DCCA0 @default.
- Q83385905 P356 Q83385905-EA21B687-9136-4070-B0A5-01ECFAE85F0F @default.
- Q83385905 P433 Q83385905-8B8CF684-E82F-4CF0-959A-776BF46F8589 @default.
- Q83385905 P478 Q83385905-9DDABB33-3B6A-43E8-BFE1-7F13EAA0276C @default.
- Q83385905 P50 Q83385905-C595D3AE-4C3B-45A0-8272-482DB236CC22 @default.
- Q83385905 P577 Q83385905-F7133DDA-5F1F-4BA6-BD2C-55C9AB951390 @default.
- Q83385905 P698 Q83385905-2DBE351C-AE1E-4F1A-822F-8323C7892864 @default.
- Q83385905 P921 Q83385905-00C03D0E-E0E5-4289-A152-EA7474E2A2E2 @default.
- Q83385905 P921 Q83385905-B74D7D2C-3B5E-44F0-91E0-3F0A995590F5 @default.
- Q83385905 P921 Q83385905-FF08902B-5DAA-4542-B3EE-80A9F897E540 @default.
- Q83385905 P356 03007990902779749 @default.
- Q83385905 P698 19231913 @default.
- Q83385905 P1433 Q5195063 @default.
- Q83385905 P1476 "Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study" @default.
- Q83385905 P2093 "A D Ruiz" @default.
- Q83385905 P2093 "A Fisher" @default.
- Q83385905 P2093 "B R Makos" @default.
- Q83385905 P2093 "C R Frei" @default.
- Q83385905 P2093 "C U Oramasionwu" @default.
- Q83385905 P2093 "J L Ruiz" @default.
- Q83385905 P2093 "J R Schein" @default.
- Q83385905 P2093 "M I Restrepo" @default.
- Q83385905 P2093 "M K Raut" @default.
- Q83385905 P2093 "R T Attridge" @default.
- Q83385905 P2093 "S H Mody" @default.
- Q83385905 P2093 "T C Jaso" @default.
- Q83385905 P304 "859-868" @default.
- Q83385905 P31 Q13442814 @default.
- Q83385905 P356 "10.1185/03007990902779749" @default.
- Q83385905 P433 "4" @default.
- Q83385905 P478 "25" @default.
- Q83385905 P50 Q42838613 @default.
- Q83385905 P577 "2009-04-01T00:00:00Z" @default.
- Q83385905 P698 "19231913" @default.
- Q83385905 P921 Q165399 @default.
- Q83385905 P921 Q421713 @default.
- Q83385905 P921 Q424193 @default.